172 related articles for article (PubMed ID: 18559610)
1. Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia.
Klisovic RB; Blum W; Wei X; Liu S; Liu Z; Xie Z; Vukosavljevic T; Kefauver C; Huynh L; Pang J; Zwiebel JA; Devine S; Byrd JC; Grever MR; Chan K; Marcucci G
Clin Cancer Res; 2008 Jun; 14(12):3889-95. PubMed ID: 18559610
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia.
Klisovic RB; Blum W; Liu Z; Xie Z; Kefauver C; Huynh L; Zwiebel JA; Devine SM; Byrd JC; Grever MR; Chan KK; Marcucci G
Leuk Lymphoma; 2014 Jun; 55(6):1332-6. PubMed ID: 24015841
[TBL] [Abstract][Full Text] [Related]
3. Biochemical modulation of aracytidine (Ara-C) effects by GTI-2040, a ribonucleotide reductase inhibitor, in K562 human leukemia cells.
Chen P; Aimiuwu J; Xie Z; Wei X; Liu S; Klisovic R; Marcucci G; Chan KK
AAPS J; 2011 Mar; 13(1):131-40. PubMed ID: 21191677
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study.
Shibata SI; Doroshow JH; Frankel P; Synold TW; Yen Y; Gandara DR; Lenz HJ; Chow WA; Leong LA; Lim D; Margolin KA; Morgan RJ; Somlo G; Newman EM
Cancer Chemother Pharmacol; 2009 Nov; 64(6):1149-55. PubMed ID: 19322566
[TBL] [Abstract][Full Text] [Related]
5. A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonuclotide reductase, in acute leukemias: a California Cancer Consortium study.
Kirschbaum MH; Frankel P; Synold TW; Xie Z; Yen Y; Popplewell L; Chen R; Aljitawi O; Tuscano JM; Chan KK; Newman EM
Leuk Lymphoma; 2016 Oct; 57(10):2307-14. PubMed ID: 26895565
[TBL] [Abstract][Full Text] [Related]
6. Targeted delivery of antisense oligodeoxynucleotide by transferrin conjugated pH-sensitive lipopolyplex nanoparticles: a novel oligonucleotide-based therapeutic strategy in acute myeloid leukemia.
Jin Y; Liu S; Yu B; Golan S; Koh CG; Yang J; Huynh L; Yang X; Pang J; Muthusamy N; Chan KK; Byrd JC; Talmon Y; Lee LJ; Lee RJ; Marcucci G
Mol Pharm; 2010 Feb; 7(1):196-206. PubMed ID: 19852511
[TBL] [Abstract][Full Text] [Related]
7. A phase I pharmacokinetic and pharmacodynamic study of GTI-2040 in combination with gemcitabine in patients with solid tumors.
Malik L; Zwiebel A; Cooper J
Cancer Chemother Pharmacol; 2018 Sep; 82(3):533-539. PubMed ID: 30022224
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia.
Odenike OM; Larson RA; Gajria D; Dolan ME; Delaney SM; Karrison TG; Ratain MJ; Stock W
Invest New Drugs; 2008 Jun; 26(3):233-9. PubMed ID: 18217206
[TBL] [Abstract][Full Text] [Related]
9. GTI-2040, an antisense agent targeting the small subunit component (R2) of human ribonucleotide reductase, shows potent antitumor activity against a variety of tumors.
Lee Y; Vassilakos A; Feng N; Lam V; Xie H; Wang M; Jin H; Xiong K; Liu C; Wright J; Young A
Cancer Res; 2003 Jun; 63(11):2802-11. PubMed ID: 12782585
[TBL] [Abstract][Full Text] [Related]
10. A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors.
Desai AA; Schilsky RL; Young A; Janisch L; Stadler WM; Vogelzang NJ; Cadden S; Wright JA; Ratain MJ
Ann Oncol; 2005 Jun; 16(6):958-65. PubMed ID: 15824081
[TBL] [Abstract][Full Text] [Related]
11. A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma.
Stadler WM; Desai AA; Quinn DI; Bukowski R; Poiesz B; Kardinal CG; Lewis N; Makalinao A; Murray P; Torti FM
Cancer Chemother Pharmacol; 2008 Apr; 61(4):689-94. PubMed ID: 17569043
[TBL] [Abstract][Full Text] [Related]
12. A phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer: a study of the PMH phase II consortium.
Leighl NB; Laurie SA; Chen XE; Ellis P; Shepherd FA; Knox JJ; Goss G; Burkes RL; Pond GR; Dick C; Yen Y; Zwiebel JA; Moore MJ
J Thorac Oncol; 2009 Sep; 4(9):1163-9. PubMed ID: 19704337
[TBL] [Abstract][Full Text] [Related]
13. Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison.
Kern W; Aul C; Maschmeyer G; Schönrock-Nabulsi R; Ludwig WD; Bartholomäus A; Bettelheim P; Wörmann B; Büchner T; Hiddemann W
Leukemia; 1998 Jul; 12(7):1049-55. PubMed ID: 9665189
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity.
Marcucci G; Stock W; Dai G; Klisovic RB; Liu S; Klisovic MI; Blum W; Kefauver C; Sher DA; Green M; Moran M; Maharry K; Novick S; Bloomfield CD; Zwiebel JA; Larson RA; Grever MR; Chan KK; Byrd JC
J Clin Oncol; 2005 May; 23(15):3404-11. PubMed ID: 15824414
[TBL] [Abstract][Full Text] [Related]
15. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia.
Feldman EJ; Lancet JE; Kolitz JE; Ritchie EK; Roboz GJ; List AF; Allen SL; Asatiani E; Mayer LD; Swenson C; Louie AC
J Clin Oncol; 2011 Mar; 29(8):979-85. PubMed ID: 21282541
[TBL] [Abstract][Full Text] [Related]
16. Enzyme kinetics of GTI-2040, a phosphorothioate oligonucleotide targeting ribonucleotide reductase.
Wei X; Dai G; Liu Z; Cheng H; Xie Z; Klisovic R; Marcucci G; Chan KK
Drug Metab Dispos; 2008 Nov; 36(11):2227-33. PubMed ID: 18653746
[TBL] [Abstract][Full Text] [Related]
17. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia.
Feldman EJ; Alberts DS; Arlin Z; Ahmed T; Mittelman A; Baskind P; Peng YM; Baier M; Plezia P
J Clin Oncol; 1993 Oct; 11(10):2002-9. PubMed ID: 8410125
[TBL] [Abstract][Full Text] [Related]
18. CD33-Targeted Lipid Nanoparticles (aCD33LNs) for Therapeutic Delivery of GTI-2040 to Acute Myelogenous Leukemia.
Li H; Xu S; Quan J; Yung BC; Pang J; Zhou C; Cho YA; Zhang M; Liu S; Muthusamy N; Chan KK; Byrd JC; Lee LJ; Marcucci G; Lee RJ
Mol Pharm; 2015 Jun; 12(6):2010-8. PubMed ID: 25871632
[TBL] [Abstract][Full Text] [Related]
19. Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia.
Schimmer AD; Estey EH; Borthakur G; Carter BZ; Schiller GJ; Tallman MS; Altman JK; Karp JE; Kassis J; Hedley DW; Brandwein J; Xu W; Mak DH; LaCasse E; Jacob C; Morris SJ; Jolivet J; Andreeff M
J Clin Oncol; 2009 Oct; 27(28):4741-6. PubMed ID: 19652057
[TBL] [Abstract][Full Text] [Related]
20. Preclinical toxicity and toxicokinetics of GTI-2040, a phosphorothioate oligonucleotide targeting ribonucleotide reductase R2.
Ferdinandi ES; Vassilakos A; Lee Y; Lightfoot J; Fitsialos D; Wright JA; Young AH
Cancer Chemother Pharmacol; 2011 Jul; 68(1):193-205. PubMed ID: 20886212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
